GlassScriptPhysician profile
Sumner R Cullom
NPI 1902885015
$806.40
in general payments reported to CMS, 2019-2025
15 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $56.98 · 2021: $42.81 · 2022: $108 · 2023: $64.08 · 2024: $215 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $193.45 | 2024 | Breztri, Airsupra |
| Novo Nordisk INC | $139.88 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $106.37 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $70.97 | 2019-2020 | |
| Abbvie INC. | $61.97 | 2021-2022 | |
| Amgen INC. | $48.62 | 2019 | |
| Glaxosmithkline, LLC. | $30.19 | 2022-2023 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $26.06 | 2023 | Quviviq |
| Shire North American Group INC | $25.16 | 2019 | |
| Scpharmaceuticals INC. | $21.45 | 2024 | |
| Exact Sciences Corporation | $20.93 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $19.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.92 | 2022 | |
| Esperion Therapeutics, INC. | $11.80 | 2021 | |
| Astellas Pharma US INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumner Cullom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.